NCT04701476 2026-04-16
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Teclison Ltd.
Phase 2 Recruiting
Teclison Ltd.
Regeneron Pharmaceuticals
Parabilis Medicines, Inc.
Delcath Systems Inc.
AstraZeneca
Adagene Inc
Oncolytics Biotech
AbbVie
Sapience Therapeutics
Taiho Pharmaceutical Co., Ltd.